Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Myeloproliferative neoplasm laboratory findings

Introduction

Overview

Overview

Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.

Laboratory Findings

Laboratory Findings

Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4][5][6]

  • Blood chemistry
  • The following blood levels may be elevated:
  • Bleeding and clotting factors
  • The following blood parameters may be elevated:
  • Flow cytometry helps determine the type of cells that are present.
  • Chromosome changes that may occur in some people with leukemia include:
  • Similar to cytogenetics, but more specific for particular chromosomal translocations
  • Polymerase chain reaction
  • Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
  • Neutrophil alkaline phosphatase level
  • Vitamin B12 (or B12 binding capacity) level
  • Erythropoietin level
  • Molecular testing for JAK2, CALR, and MPL mutations
Gallery
References

References

  1. ↑ Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
  2. ↑ James W. Vardiman (2009). “Chronic myelogenous leukemia, BCR-ABL1+”. American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter |month= ignored (help)
  3. ↑ Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). “Evaluation of the WHO criteria for the classification of patients with mastocytosis”. Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
  4. ↑ Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
  5. ↑ O’Brien, S. (2004). “Chronic Myelogenous Leukemia and Myeloproliferative Disease”. Hematology. 2004 (1): 146–162. doi:10.1182/asheducation-2004.1.146. ISSN 1520-4391.
  6. ↑ Murakami J, Shimizu Y (2013). “Hepatic manifestations in hematological disorders”. Int J Hepatol. 2013: 484903. doi:10.1155/2013/484903. PMC 3626309. PMID 23606974.
  7. ↑ Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). “Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review”. Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]